Larotrectinib
Brand: Vitrakvi (global)
Anticancer
NTRK selective inhibitor
Pharmacokinetics
| Half-life | 3 hours |
| Tmax | 1 h |
| Protein Binding | 70 % |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | CNS penetration adequate; rapid onset; strong response rate in NTRK fusion solid tumours. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Dizziness, fatigue, nausea, hepatotoxicity
Contraindications:
Severe hepatic impairment
Precautions:
Monitor LFTs regularly; dose adjustment in moderate hepatic impairment.